An attractive aspect of our study is the potential for the translation of our findings into clinical trials by targeting multiple molecular in the regulatory axis, and PPFIA1/PARP1 appears to have an oncogenic role after downregulation of miR-181a in CML. This evidence concerns the gene PARP1 and chronic myelogenous leukemia, BCR-ABL1 positive.